tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Oruka Therapeutics initiated with a Buy at BTIG

BTIG initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $44 price target The firm, which expects Oruka’s ORKA-001 and ORKA-002 monoclonal antibodies to thrive as monotherapies and also potentially in combination, sees “compelling reasons to believe” that ORKA-001 and ORKA-021 could eventually be confirmed with differentiated efficacy in the indications of psoriasis and psoriatic arthritis.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1